Grade: Pharmaceutical Grade

Factory Location: Changzhou

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Monthly Production Capacity: 500kgs

Contract Manufacturing: CRO,CMO

Packaging Information: 1kgs,5kgs,10kgs,25kgs,

Delivery Lead Time: 1 week

Sample Provided: yes

Payment Terms: L/C

Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.